Biography

Andrew Ashe is president and chief operating officer of Verve Therapeutics. Mr. Ashe is an accomplished biotech executive with over 20 years of experience in operations and legal management. Prior to joining Verve, he served as a senior executive and general counsel for several biotech companies, including Applied Genetic Technologies Corporation and Dyax Corp. During his tenure at Dyax, Mr. Ashe managed all legal and administrative functions during a period of growth in which market capitalization increased from $180 million to $6 billion. While at Dyax, he also established more than 75 revenue-generating collaborations with biotech and pharma companies in the United States, Europe, India, Australia, and Japan. Dyax was acquired in 2016. Previously, Mr. Ashe was a member of the business law practices at Prince Lobel Tye LLP and Nutter, McClennen & Fish LLP. Prior to attending law school, he served as a trading specialist and senior analyst at the American and New York Stock Exchanges. He holds a B.A. in finance from the Isenberg School of Management at University of Massachusetts and a J.D. from the George Washington University School of Law.